BTIG Reiterates Buy on Maze Therapeutics, Maintains $46 Price Target

Benzinga · 1d ago
BTIG analyst Julian Harrison reiterates Maze Therapeutics (NASDAQ:MAZE) with a Buy and maintains $46 price target.